January 31 (SeeNews) - Bulgarian pharmaceuticals trader Sopharma Trading [BUL:SFT] said that its non-consolidated net profit surged to 16.8 million levs ($9.37 million/8.59 million euro) in 2022 from 5.2 million levs a year earlier.
Revenue rose to 1.108 billion levs last year from 974.3 million levs in 2021, Sopharma Trading said in an interim financial statement on Monday.
At the same time, operating expenses grew to 1.09 billion levs from 966.5 million levs, mainly due to revaluation of assets.
Sopharma Trading's sales jumped by 13.5% on the year to 1.103 billion levs in 2022. Of that, sales of products in the company's pharmacy network held a 52.18% share, while sales to hospitals contributed 28.98%. The company said it controlled 21.79% of the Bulgarian pharmaceuticals market in 2022, including a 19% share of the pharmacy market, and 29.56% of the hospital market.
Sopharma Trading is a unit of Bulgarian pharmaceuticals producer Sopharma [BUL:SFA], which held a stake of 87.25% in the company at the end of last year.
As of 1025 CET on Tuesday, Sopharma Trading's shares traded 3.70% lower at 5.72 levs on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)